53
Views
1
CrossRef citations to date
0
Altmetric
Clinical Features - Letter to the Editor

Pharmacokinetic/pharmacodynamic properties and efficacy/safety of U-500R from randomized clinical studies

, &
 

Declaration of interest

CSA Brusko, AD Taylor and JA Jackson are full-time employees of Eli Lilly and Company and/or one of its subsidiaries; JA Jackson and CSA Brusko are minor stockholders in Eli Lilly and Company. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.